SCHEMBL11358564

SCHEMBL11358564

CCN(Cc1cccc(B2OC(C)(C)C(C)(C)O2)c1)C(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
LIPG Q9Y5X9 2/20 0.44
LPL P06858 1/20 0.44
AAK1 Q2M2I8 2/20 0.40
PTGES O14684 1/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
AKT1 P31749 2/20 0.35
TSPO P30536 1/20 0.35
HIF1A Q16665 2/20 0.35
SIGMAR1 Q99720 1/20 0.35
ALDH1A1 P00352 1/20 0.34
NPFFR1 Q9GZQ6 1/20 0.34
NPFFR2 Q9Y5X5 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11362213 0.88 PRMT5 (0.46) PRMT5WDR77LIPGLPLAAK1
SCHEMBL24386987 0.85 LIPG (0.50) PRMT5WDR77LIPGLPLAAK1
SCHEMBL29750018 0.85 LIPG (0.50) PRMT5WDR77LIPGLPLAAK1
SCHEMBL15805918 0.83 PRMT5 (0.44) PRMT5WDR77LIPGLPLAAK1
SCHEMBL11358431 0.81 CTSB (0.47) PTGESCTSLCTSBCTSSAKT1
SCHEMBL2592478 0.81 PRMT5 (0.57) PRMT5WDR77LIPGLPLAAK1
SCHEMBL29591259 0.81 PRMT5 (0.57) PRMT5WDR77LIPGLPLAAK1
SCHEMBL16169736 0.81 PRMT5 (0.46) PRMT5WDR77LIPGLPLAAK1
SCHEMBL11425579 0.81 PRMT5 (0.50) PRMT5WDR77LIPGLPLAAK1
SCHEMBL17606848 0.80 PRMT5 (0.46) PRMT5WDR77LIPGLPLAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 EP disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 US disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 US disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 US disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 US disclosed
WO-2011034078-A1 GLYCINE COMPOUND アステラス製薬株式会社 (JP) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184520-A1 GLYCINE COMPOUND SLC5A1, AQP1, VAPB PRMT5 2196/4885WDR77 2124/4885LIPG 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.